Merck KGaA's Old Story Is Dead. The Cash Flow Says So.

Merck KGaA, the German science group based in Darmstadt, has an old story hanging over it. Healthcare is dragging. Mavenclad, its MS drug, lost U.S. market exclusivity. Specialty Care is bleeding. The market prices the company like a pharma business losing its best product.

The Q2 2026 numbers say something else. Life Science grew 8% organically. Electronics posted 11.7% organic growth, with the Semiconductor Solutions sub-segment surging 17.3% on AI demand. Group EBITDA pre margin expanded 1.6 percentage points to 29.4%, and management raised the full-year outlook across every metric that matters.

The market is still pricing the Healthcare pain. But the cash flow and margin path in the other two businesses already say the story has changed.

The old story

Merck KGaA — not to be confused with Merck & Co., the U.S. pharma company — has three businesses: Life Science, Electronics, and Healthcare. Healthcare got the headline share. Mavenclad lost U.S. market exclusivity and sales will go to zero there starting in August 2026. Specialty Care dropped 5.8% organically in Q2. The group's reported profit after tax fell 24.7% year-over-year to €494 million, weighed down by higher R&D spending and one-time adjustments. Reported EPS dropped to €1.13 from €1.50.

If you only read the top-line GAAP headline, Healthcare drag looks like a compounding problem. The company's 2026 guidance assumes zero U.S. Mavenclad revenue from August forward. Healthcare is expected to decline 2%–4% organically for the full year.

That's the story the market anchored to.

The proof path

EBITDA pre — earnings before interest, taxes, depreciation, and amortization, plus adjustments for R&D and other structural items — is the metric that cuts through the noise. It strips out the accounting hits and one-off costs and shows what the operating engine is actually generating.

Q2 EBITDA pre grew 9.3% organically to €1.6 billion. The margin expanded to 29.4% from 27.8%. That's a 1.6-percentage-point expansion in a single quarter. On a €21 billion-plus annual revenue base, a sustained margin of that level generates materially more cash than the market has been pricing.

Now look at the two segments doing the heavy lifting.

Life Science grew 8% organically to €2.4 billion. Process Solutions — the biopharma manufacturing equipment and consumables division — delivered 15% organic growth. The segment's EBITDA pre was €700 million, with margin expanding 50 basis points to 29%. The book-to-bill ratio (orders received versus orders fulfilled) was above one in the first half, meaning demand is outpacing what the company can currently deliver. Management expects full-year Process Solutions growth to land at the upper end of the 8%–12% range it had already guided to — not a new number, but a confirmation the momentum isn't fading.

Electronics is the real inflection. Organic sales grew 11.7%, driven by Semiconductor Solutions' 17.3% organic surge on AI-driven demand for advanced logic and memory nodes. EBITDA pre in the segment was €244 million, up 87.5% organically. The margin jumped roughly 200 basis points to 28%. Management expects advanced memory chip shortages and elevated prices to persist through at least the second half of 2027. This isn't a one-quarter bounce. The segment was flat or declining organically as recently as Q2 2024, when the company flagged a "market inflection" that investors treated as cautious optimism. Two years later, the inflection is generating margin-expanding cash flow.

Healthcare is the drag, but the drag has a floor. Mavenclad sales declined 10.2% organically to €275 million and will cease in the U.S. from August. But Rare Diseases, bolstered by the SpringWorks acquisition, generated €115 million in Q2 and contributed a +5.4% portfolio effect. Auxilium and Gomekli together produced €207 million in the first half. Cardiometabolic grew 1.2%, led by Euthyrox at +7.8% organic. The Mavenclad cliff is real and priced in. What's less obvious is that the remaining Healthcare franchise still generates €747 million of quarterly EBITDA pre at a 34.7% margin — the highest-margin segment in the group.

Why the market hasn't moved

The ADR trades at roughly 23–25 times trailing earnings. That's not cheap by historical standards. But the valuation hasn't repriced for three reasons.

First, the Healthcare narrative is sticky. Generic competition for Mavenclad is visible, tangible, and ongoing every quarter. It's the easiest story to hang onto.

Second, the guidance upgrade wasn't dramatic — the group raised its organic sales growth range to 1%–3% (from 0%–3%) and its EBITDA pre range to €5.9–€6.3 billion (from €5.7–€6.1 billion). The upgrade was measured. It signaled confidence without fireworks.

Third, the company is about to acquire Bio-Techne, which adds near-term execution risk and requires meaningful cash deployment. Net financial debt stood at €9.2 billion as of June 30, up from recent quarters primarily due to dividend payments and acquisition preparation. Management is right to focus on cash generation and deleveraging ahead of the deal. But the market treats the Bio-Techne acquisition as a distraction rather than the growth multiplier it's designed to be — €140 million in annual run-rate cost synergies by year three, immediate accretion to sales growth and EBITDA margin, and a clear path to EPS accretion.

The rerating bridge

Here's the financial math that makes the case concrete.

Take the midpoint of the upgraded EPS pre guidance: €8.25. That implies full-year EBITDA pre of roughly €6.1 billion at the guidance midpoint. If the EBITDA pre margin sustains at or near the Q2 level of 29.4%, the operating engine is generating close to €6 billion of cash earnings on €21 billion-plus in revenue.

Compare that to 2025, when group EBITDA pre was €6.1 billion but the margin was roughly 28.9% and Healthcare was still contributing Mavenclad revenue at scale. The same €6 billion is being generated with a leaner, higher-margin mix — Electronics at 28% margin and growing, Life Science at 29% margin and growing, Healthcare declining in sales but maintaining 34.7% margin on what remains.

The margin quality is improving even as top-line growth stays measured. That's the inflection. The business is getting more profitable at roughly the same revenue level as last year.

An earlier analyst price target from April set a Buy rating with €127 per share. The German-listed shares were trading in the €110–115 range ahead of Q2 results and moved modestly higher on the earnings release. The ADR has languished, reflecting the gap between what the operating data shows and what the market narrative still clings to.

What could go wrong

Three scenarios break the thesis.

Process Solutions normalizes too fast. The Q2 uplift in biopharma manufacturing demand was partly driven by inventory destocking by end customers, and management acknowledged that the temporary uplift is already beginning to normalize. If the segment drops back below mid-single-digit organic growth before Bio-Techne closes, the Life Science growth story thins.

Electronics turns with memory. The semiconductor segment's surge depends on continued AI-driven demand for advanced nodes and elevated memory prices. If the memory supply/demand balance corrects faster than expected — management's own forecast assumes shortages persisting through H2 2027 — the Electronics margin expansion reverses quickly. This segment went flat in 2024. It can go flat again.

Bio-Techne integration stalls. The acquisition is the largest strategic move in the company's recent history. Regulatory delays, integration missteps, or failure to capture the promised €140 million in synergies would undermine the cash flow case and leave the balance sheet carrying extra debt for no return.

The setup

The market is still pricing Merck KGaA like a Healthcare company in decline. The numbers say it's increasingly a Life Science and Electronics company with a high-margin Healthcare franchise that's past its worst.

The guidance upgrade, the margin expansion, the semiconductor inflection — these point to a business that's generating more cash at roughly the same revenue level as last year, while the narrative hasn't caught up.

The invalidation condition is clear: if Process Solutions growth drops below 5% organically and Electronics EBITDA margin fails to hold above 25%, the rerating case collapses. In that scenario, cut the position. The thesis depends on both growth engines staying lit.

If they do, the operating setup is already cleaner than the stock price suggests.